Related Experiment Videos

Cancer-associated glycosphingolipid antigens: their structure, organization, and function

S Hakomori1

  • 1Pacific Northwest Research Institute and Department of Pathobiology University of Washington, Seattle, WA 98122, USA.

Acta Anatomica
|October 22, 1998
PubMed

Insights

Tumor-associated glycosphingolipid (GSL) antigens are key targets for cancer immunotherapy. Understanding their role in cell adhesion and signaling may lead to novel antiadhesion and ortho-signaling therapies.

Area of Science:

  • Biochemistry
  • Immunology
  • Oncology

Background:

  • Tumor-associated glycosphingolipid (GSL) antigens are prevalent in experimental and human cancers.
  • Monoclonal antibodies have identified numerous GSL antigen structures, though none are strictly tumor-specific.
  • Antibody reactivity with tumors often stems from altered GSL organization in cancer cell membranes.

Purpose of the Study:

  • To explore the structural and functional roles of tumor-associated GSL antigens.
  • To investigate the involvement of GSLs in tumor cell adhesion and signal transduction.
  • To identify potential therapeutic targets for cancer treatment.

Main Methods:

  • Structural identification of GSL antigens using monoclonal antibodies.
  • Analysis of membrane GSL organization in tumor versus normal cells.
  • Investigation of GSLs as adhesion molecules and their interaction with carbohydrate-binding proteins.

Main Results:

  • Clustered GSL antigens, organized within microdomains with transducer molecules, are implicated in tumor cell adhesion and signal transduction.
  • Certain GSL antigens function as adhesion molecules, interacting with complementary carbohydrates or proteins on target cells.
  • This adhesion and signaling mechanism is potentially involved in initiating cancer metastasis.

Conclusions:

  • Elucidating the adhesion/signaling mechanism of GSL antigens can lead to new therapeutic strategies like antiadhesion or ortho-signaling therapy.
  • Tumor-associated GSL antigens represent promising targets for cancer immunotherapy, including vaccine development.

Related Concept Videos